CCL5 secreted from bone marrow stromal cells stimulates the migration and invasion of Huh7 hepatocellular carcinoma cells via the PI3K-Akt pathway

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 333-343

  Bai, Huili ^a   Weng, Yaguang ^a   Bai, Shunjie ^a   Jiang, Yingjiu ^a   Li, Baolin ^a   He, Fang ^a   Zhang, Ruyi ^a   Yan, Shujuan ^a   Deng, Fang ^a   Wang, Jing ^a   Shi, Qiong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bone metastases; CCL5; Hepatocellular carcinoma; Marrow stromal cells; Microenvironment

Indexed keywords

GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANTES; CCL5 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; BONE METASTASIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STROMA CELL; TUMOR INVASION; ANIMAL; BONE MARROW CELL; CELL MOTION; EXPERIMENTAL LIVER NEOPLASM; LIVER TUMOR; METABOLISM; PATHOLOGY; SCID MOUSE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BONE MARROW CELLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL5; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; NEOPLASM INVASIVENESS; STROMAL CELLS;

EID: 84902588701     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2421     Document Type: Article

References (55)

1. Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458, 2010.
2. Ma W, Wong CC, Tung EK, Wong CM and Ng IO: RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology 57: 152-161, 2013.
3. Ho CL, Chen S, Yeung DW and Cheng TK: Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48: 902-909, 2007.
4. Natsuizaka M, Omura T, Akaike T, et al: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20: 1781-1787, 2005.
5. Xiang ZL, Zeng ZC, Tang ZY, et al: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 9: 176, 2009.
6. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8: 98-101, 1989.
7. Chung LW, Baseman A, Assikis V and Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20, 2005.
8. Chackal-Roy M, Niemeyer C, Moore M and Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84: 43-50, 1989.
9. Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini F III: Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19, 2011.
10. Maestroni GJ, Hertens E and Galli P: Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 55: 663-667, 1999.
11. Kucerova L, Matuskova M, Hlubinova K, Altanerova V and Altaner C: Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 9: 129, 2010.
12. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
13. Lin JT, Wang JY, Chen MK, et al: Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res 319: 2216-2229, 2013.
14. Khakoo AY, Pati S, Anderson SA, et al: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203: 1235-1247, 2006.
15. Zhang C, Soori M, Miles FL, et al: Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells. Prostate 71: 157-167, 2011.
16. Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, et al: Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis 34: 2330-2340, 2013.
17. Mizuguchi T, Hui T, Palm K, et al: Enhanced proliferation and differentiation of rat hepatocytes cultured with bone marrow stromal cells. J Cell Physiol 189: 106-119, 2001.
18. Jing Y, Han Z, Liu Y, et al: Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One 7: e43272, 2012.
19. Li GC, Ye QH, Dong QZ, Ren N, Jia HL and Qin LX: Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models. Oncol Rep 29: 713-719, 2013.
20. Li GC, Ye QH, Xue YH, et al: Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci 101: 2546-2553, 2010.
21. Niess H, Bao Q, Conrad C, et al: Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 254: 767-775, 2011.
22. Qiao L, Xu Z, Zhao T, et al: Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18: 500-507, 2008.
23. Ho IA, Toh HC, Ng WH, et al: Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31: 146-155, 2013.
24. Sahin H, Trautwein C and Wasmuth HE: Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 7: 682-690, 2010.
25. Makinoshima H and Dezawa M: Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett 583: 3697-3703, 2009.
26. Luther SA and Cyster JG: Chemokines as regulators of T cell differentiation. Nat Immunol 2: 102-107, 2001.
27. Charni F, Friand V, Haddad O, et al: Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 1790: 1314-1326, 2009.
28. Sutton A, Friand V, Papy-Garcia D, et al: Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther 6: 2948-2958, 2007.
29. Liou JM, Lin JT, Huang SP, et al: RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol 43: 115-123, 2008.
30. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y and Toma H: High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 171: 2171-2175, 2004.
31. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM and Silberstein LE: Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24: 1030-1041, 2006.
32. Tyner JW, Uchida O, Kajiwara N, et al: CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 11: 1180-1187, 2005.
33. Bao M, Chen Z, Xu Y, et al: Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int 32: 331-338, 2012.
34. Palagyi A, Neveling K, Plinninger U, et al: Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 9: 127, 2010.
35. Shi F, Shi M, Zeng Z, et al: PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896, 2011.
36. Chen J, Liu WB, Jia WD, et al: Overexpression of mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int J Oncol 44: 247-255, 2014.
37. Montella L, Addeo R, Palmieri G, et al: Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. Cancer Chemother Pharmacol 65: 1137-1143, 2010.
38. Crawford BA, Kam C, Pavlovic J, et al: Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144: 239-248, 2006.
39. Lu YR, Yuan Y, Wang XJ, et al: The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 7: 245-251, 2008.
40. Wang SW, Wu HH, Liu SC, et al: CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 7: e35101, 2012.
41. Cambien B, Richard-Fiardo P, Karimdjee BF, et al: CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One 6: e28842, 2011.
42. Vaday GG, Peehl DM, Kadam PA and Lawrence DM: Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66: 124-134, 2006.
43. Gallo M, De Luca A, Lamura L and Normanno N: Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 23: 597-604, 2012.
44. Long H, Xie R, Xiang T, et al: Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-ΚB-mediated MMP-9 upregulation. Stem Cells 30: 2309-2319, 2012.
45. Barashi N, Weiss ID, Wald O, et al: Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 58: 1021-1030, 2013.
46. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
47. Mo W, Chen J, Patel A, et al: CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 152: 1077-1090, 2013.
48. Liu H, Pan Z, Li A, et al: Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 5: 373-378, 2008.
49. Li X, Yang Z, Song W, et al: Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth factor via the PTEM/PI3K/Akt pathway. Int J Oncol 43: 793-802, 2013.
50. Suthiphongchai T, Promyart P, Virochrut S, Tohtong R and Wilairat P: Involvement of ERK1/2 in invasiveness and metastatic development of rat prostatic adenocarcinoma. Oncol Res 13: 253-259, 2003.
51. Diaz-Gil JJ, Garcia-Monzon C, Rua C, et al: The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats. Histol Histopathol 23: 583-591, 2008.
52. Roomi MW, Kalinovsky T, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol 44: 27-34, 2014.
53. Xiang ZL, Zeng ZC, Fan J, et al: Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 17: 5463-5472, 2011.
54. Wang YH, Dong YY, Wang WM, et al: Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-ΚB pathways induced by paracrine cytokines. J Exp Clin Cancer Res 32: 51, 2013.
55. Gao J, Ding F, Liu Q and Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem 376: 21-32, 2013.